title: [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
abstract: Glucagon-like peptide-1 (GLP-1) receptor agonists are a new group of drugs for the treatment of type 2 diabetes mellitus (DM2). In the present article, we review the available evidence on the efficacy of GLP-1 receptor agonists as glucose-lowering agents, their place in therapeutic algorithms, and the clinical factors associated with a favorable treatment response. Finally, we describe the clinical characteristics of patients who may benefit from these drugs.
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y la Nutrición (CIBERobn CB06/003), Instituto de Salud Carlos III, España.
authors.forename: José Carlos
authors.initials: JC
authors.lastname: Fernández-García
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España; Centro de Investigación Biomédica en Red-Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem), Instituto de Salud Carlos III, España. Electronic address: nataliacolomo@gmail.com.
authors.forename: Natalia
authors.initials: N
authors.lastname: Colomo
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y la Nutrición (CIBERobn CB06/003), Instituto de Salud Carlos III, España.
authors.forename: Francisco José
authors.initials: FJ
authors.lastname: Tinahones
mesh_terms: D050260:Carbohydrate Metabolism / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D000069450:Liraglutide / Q000494:pharmacology* / Q000627:therapeutic use; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D014688:Venoms / Q000494:pharmacology* / Q000627:therapeutic use; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; D000067758:Glucagon-Like Peptide-2 Receptor
chemical_list: D000077270:Exenatide; D007004:Hypoglycemic Agents; D007328:Insulin; D000069450:Liraglutide; D010455:Peptides; D014688:Venoms; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; C479460:lixisenatide; D000067758:Glucagon-Like Peptide-2 Receptor
keywords: Agonista del receptor del péptido similar al glucagón; Diabetes; Diabetes mellitus; Efficacy; Eficacia; Exenatida; Exenatida semanal; Exenatide; Glucagon-like peptide-1 receptor agonist; Hipertensión; Hipoglucemias; Hypertension; Hypoglycemias; Liraglutida; Liraglutide; Lixisenatida; Lixisenatide; Obesidad; Obesity; Weekly exenatide